Abstracts tagged "Genetic Biomarkers"

Abstract Number: 2726 • 2013 ACR/ARHP Annual Meeting
A Polymorphism In The Mif Gene Is Associated With Cardiovascular Morbidity In Systemic Lupus Erythematosus – a Pilot Study
Eric F. Morand, Kathryn Connelly and Alberta Y. Hoi, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia
Background/Purpose: Chronic inflammation is believed to be responsible for accelerated atherosclerotic cardiovascular disease (CVD) in patients with SLE. Macrophage migration inhibitory factor (MIF) is a…
Abstract Number: 2558 • 2013 ACR/ARHP Annual Meeting
Bone Morphogenic Protein Receptor 2 (BMPR2) Gene Mutations Are Associated To The Development Of Isolated Pulmonary Arterial Hypertension (PAH) In Systemic Sclerosis (SSc) Patients
Tatiana Sofia Rodriguez-Reyna¹, Jose Luis Hernandez-Oropeza², Tomas Rene Pulido-Zamudio³, Felipe Massó⁴, Jessica Gutierrez-Manjarrez¹, Alexandra Rueda de Leon-Aguirre¹, Julio Sandoval-Zarate³ and Carlos Rodriguez-Osorio⁵, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Pulmonary Circulation Clinic, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³Pulmonary Circulation Clinic, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁴Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁵Intensive Care Unit, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Isolated pulmonary arterial hypertension (PAH) secondary to Systemic Sclerosis (SSc) is a severe life-threatening complication. Several pathogenic pathways have been implicated in its development.…
Abstract Number: 2517 • 2013 ACR/ARHP Annual Meeting
The Interferon-Alpha Signature In Patients With Serologically Active Clinically Quiescent Systemic Lupus Erythematosus
Amanda J. Steiman¹, Murray B. Urowitz², Dominique Ibanez², Carolina Landolt-Marticorena³, Joan E. Wither⁴ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Interferon-α (IFN-α) plays a prominent pro-inflammatory role in SLE. Studies suggest clinical/serologic discordance may illuminate systemic lupus erythematosus (SLE) pathophysiology, as peripheral IFN-α production…
Abstract Number: 1904 • 2013 ACR/ARHP Annual Meeting
Gene Expression In Whole Blood Predicts The Abatacept–Methotrexate Combination Responsiveness In Rheumatoid Arthritis: Preliminary Results From The Power Doppler Ultrasonography IM101-179 Study
T Lequerré¹, C Derambure¹, Maria-Antonietta d'Agostino², M Hiron³, P Gaudin⁴, C Gaillez⁵, M Le Bars⁶ and O Vittecoq¹, ¹Rouen University Hospital & Inserm U905, Rouen, France, ²AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ³Rouen University Hospital & Inserm, Rouen, France, ⁴CHU Hôpital Sud, Grenoble, France, ⁵Bristol-Myers Squibb, Rueil Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: The overall response rate (defined as low disease activity [LDA] related to DAS28[CRP]) to abatacept associated with MTX was 57.1% at 6 months in…
Abstract Number: 1396 • 2013 ACR/ARHP Annual Meeting
Survivin–positivity Increases Risk For RA and Has a Strong Additive Effect On The Shared Epitope Alleles and Antibodies To Citrullinated Peptides In Patients Of The Malaysian Epidemiological Investigation Of Rheumatoid Arthritis (MyEIRA) Study Group
Chun Lai Too¹, Shahnaz Murad², Malin Erlandsson³, Heselynn Hussein⁴, Wahinuddin Sulaiman⁵, Jasbir Singh Dhaliwal¹ and Maria Bokarewa³, ¹Institute for Medical Research, Allergy and Immunology Research Center, Jalan Pahang, Kuala Lumpur, Malaysia, ²Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Malaysia, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Medicine, Putrajaya Hospital, Putrajaya, Malaysia, ⁵Department of Medicine, Tengku Bainun Hospital, Ipoh, Perak, Malaysia
Background/Purpose: The human leukocyte antigen (HLA)-DRB1 with alleles that contain common amino acid motif QKRAA termed shared epitope (SE) confer the major locus of genetic…
Abstract Number: 1202 • 2013 ACR/ARHP Annual Meeting
Two Family Kindreds With Blau’s Syndrome Associated With Unusual NOD2 Mutations
Qingping Yao, Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: The aim of this study was to report families of Blau’s syndrome with unusual NOD2 gene variants. Methods: Two proband patients were seen, and their clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.